REMARKS

Claims 1-9, 11-12, 18, 26, and 47-51 are present in the above-identified application, claim 51 having been added by this amendment pursuant to a suggestion of the Examiner to copy a claim under 37 C.F.R. § 1.605. The suggested claim is copied exactly.

Claim 51 is fully supported by the specification. For example, at page 17, lines 27-32, the specification recites:
"Accordingly, the invention encompasses substantially purified DNA comprising DNA encoding an amino acid sequence selected from the group consisting of the amino acid sequence of: (i)

Streptococcus pyogenes DNase B enzyme as shown in Figure 4; and (ii) a sequence encoding a functional equivalent of S. pyogenes DNase B enzyme." This provides literal support for claim 51.

Moreover, this language complies with the written description requirement of the first paragraph of 35 U.S.C. § 112.

Enablement under the second paragraph of 35 U.S.C. § 112 for this claim is also clearly present, as DNA encoding this sequence was actually cloned in clone 2-6, in bacteriophage \(\lambda\gamma\text{11}.\)

The fee for one additional independent claim (\$78.00) for a large entity is enclosed. Please charge any additional fee or credit any overpayment to Deposit Account No. 13-2724.

The Examiner has set a period of one month for copying of this claim. Therefore, this amendment is timely.

The copying of suggested claims pursuant to 37 C.F.R. § 1.605(b) automatically stays ex parte prosecution with regard to

30429.39US02

a response to the outstanding Office Action dated December 28, 1995 (Paper No. 7).

Date:

January 22, 1996

Respectfully submitted

Michael B. Farber Reg. No. 32,612

Merchant & Gould 11150 Santa Monica Boulevard, Suite 400 Los Angeles, CA 90025 (310) 445-1140

> I hereby certify that this correspondence is being degosited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on

Cittle of Daysonilly

3